DSIJ Mindshare

Buzzing stock: Orient Refractories trades at all-time high level
Apurva Joshi
/ Categories: Trending, Mindshare

Buzzing stock: Orient Refractories trades at all-time high level

In just one year, Orient Refractories Limited has rallied by approximately 147 per cent making an all-time high level of Rs 319.20 from its 52-week low level of Rs 129.50 on BSE. On a YTD basis, this stock has given approximately 27 per cent returns to the investors. 

Orient Refractories is in the business of manufacturing and marketing special refractory products, systems & services to the steel industry in India and globally. It is the market leader for special refractories in India. 

One of the main reasons behind the recent rally is the strong performance that it delivered during December 2020 quarter i.e. Q3FY21. Its consolidated revenue for the quarter came in at Rs 200.88 crore, registering 19.4 per cent YoY increase, led by a rise in the demand from the steel industry. EBITDA for the quarter grew by 25.9 per cent YoY while EBITDA margin stood at 17.5 per cent. PAT came in at Rs 24.39 crore, registering a YoY increase of 23.4 per cent. 

Also, a recent rally in metal stocks was seen due to the rise in metal prices. Orient Refractories, being one of the direct beneficiaries of the metal segment, was able to witness and be a part of this rally. Demand for refractory is primarily dependent on the consumption of steel, which accounts for about 75 per cent of the total value while the remaining is used for glass, cement, non-ferrous, petrochemicals, etc. 

The company is in the process of building an R&D center at Bhiwadi (Rajasthan). Additionally, a regional shared service centre (Integrated Business Centre) would be set up in India by next year. The management is also planning to enter the foundry business in India. 

On Friday, the stock of Orient Refractories surged 4.5 per cent to Rs 319.20 (all-time high) from its previous close of Rs 305.85 on BSE. 

Previous Article Ten stocks close to their 52-week high
Next Article Gland Pharma climbs nearly 2 per cent on getting USFDA nod for generic Foscarnet Sodium injection
Print
1251 Rate this article:
4.8
Please login or register to post comments.
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR